NO20070194L - Fremgangsmater for behandling av hepatitt C - Google Patents

Fremgangsmater for behandling av hepatitt C

Info

Publication number
NO20070194L
NO20070194L NO20070194A NO20070194A NO20070194L NO 20070194 L NO20070194 L NO 20070194L NO 20070194 A NO20070194 A NO 20070194A NO 20070194 A NO20070194 A NO 20070194A NO 20070194 L NO20070194 L NO 20070194L
Authority
NO
Norway
Prior art keywords
treatment
hepatitis
methods
hcv
replication
Prior art date
Application number
NO20070194A
Other languages
English (en)
Inventor
Jeffrey Allen Campbell
Gary Mitchell Karp
Guangming Chen
Peter Seongwoo Hwang
James Takasugi
Hongyu Ren
Richard Gerald Wilde
Anthony Turpoff
Alexander Arefolov
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of NO20070194L publication Critical patent/NO20070194L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

I overensstemmelse med den foreliggende oppfinnelse er forbindelser som inhiberer viral replikasjon, foretrukket hepatitt C virus (HCV) replikasjon, blitt identifisert og fremgangsmåten for deres anvendelse er tilveiebragt. I et aspekt av oppfinnelsen er forbindelser som er anvendbare i behandling eller forebygging av en viral infeksjon tilveiebragt. I et annet aspekt av oppfinnelsen er forbindelser som er anvendbare i behandling eller forebygging av HCV infeksjon tilveiebragt.
NO20070194A 2004-07-14 2007-01-11 Fremgangsmater for behandling av hepatitt C NO20070194L (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US58748704P 2004-07-14 2004-07-14
US63497904P 2004-12-13 2004-12-13
US64558605P 2005-01-24 2005-01-24
US66534905P 2005-03-28 2005-03-28
US67544005P 2005-04-28 2005-04-28
PCT/US2005/024881 WO2006019831A1 (en) 2004-07-14 2005-07-14 Methods for treating hepatitis c

Publications (1)

Publication Number Publication Date
NO20070194L true NO20070194L (no) 2007-04-16

Family

ID=35613725

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070194A NO20070194L (no) 2004-07-14 2007-01-11 Fremgangsmater for behandling av hepatitt C

Country Status (13)

Country Link
US (2) US8013006B2 (no)
EP (1) EP1771169A1 (no)
JP (1) JP2008506702A (no)
KR (1) KR20070083484A (no)
AU (1) AU2005275181A1 (no)
BR (1) BRPI0511834A (no)
CA (1) CA2573185A1 (no)
EA (1) EA200700243A1 (no)
EC (1) ECSP077252A (no)
IL (1) IL180645A0 (no)
MX (1) MX2007000481A (no)
NO (1) NO20070194L (no)
WO (1) WO2006019831A1 (no)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007084413A2 (en) * 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
EP1771169A1 (en) 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Methods for treating hepatitis c
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
DOP2006000016A (es) * 2005-01-26 2006-07-31 Aventis Pharma Inc 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2.
CN101218224B (zh) 2005-05-13 2013-05-08 Viro化学制药公司 治疗或预防黄病毒感染的组合物和方法
CN102304075A (zh) * 2005-10-11 2012-01-04 因特蒙公司 病毒复制抑制剂
CN101384592A (zh) * 2005-12-21 2009-03-11 艾博特公司 抗病毒化合物
DK1973545T3 (da) 2005-12-23 2013-02-25 Ariad Pharma Inc Bicykliske heteroarylforbindelser
WO2007084435A2 (en) * 2006-01-13 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
MX2008011354A (es) * 2006-03-03 2008-09-15 Schering Corp Combinaciones farmaceuticas de inhibidores de proteasa del virus de hepatitis c y del sitio interno de entrada ribosomal del virus de hepatitis c.
WO2007133560A2 (en) 2006-05-08 2007-11-22 Ariad Pharmaceuticals, Inc. Acetylenic heteroaryl compounds
NZ601730A (en) * 2006-06-26 2014-04-30 Akebia Therapeutics Inc Prolyl hydroxylase inhibitors and methods of use
MX2009002921A (es) 2006-09-15 2009-04-01 Schering Corp Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico.
US7923004B2 (en) * 2006-10-13 2011-04-12 Xtl Biopharmaceuticals Ltd. 4-ethynyl pyrazole derivative compounds and methods for treatment of HCV
PT2104674E (pt) 2006-11-15 2013-07-26 Virochem Pharma Inc Análogos de tiofeno para o tratamento ou prevenção de infeções por flavivírus
KR100862113B1 (ko) 2007-01-22 2008-10-09 삼성전자주식회사 공정 변화에 대한 정보를 이용하여 공급전압/공급주파수를제어할 수 있는 장치와 방법
EP2134683A2 (en) * 2007-02-12 2009-12-23 Intermune, Inc. Novel inhibitors hepatitis c virus replication
JP5107589B2 (ja) * 2007-02-13 2012-12-26 旭化成株式会社 インドール誘導体
ES2381410T3 (es) 2007-05-04 2012-05-28 Vertex Pharmceuticals Incorporated Terapia de combinación paa el tratamiento de infecciones por VHC
US20120121540A1 (en) * 2007-08-10 2012-05-17 Franz Ulrich Schmitz Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections
DK2203431T3 (da) * 2007-09-17 2011-11-21 Abbott Lab Antiinfektiøse pyrimidiner og anvendelser heraf
EP2222672B1 (en) * 2007-11-16 2013-12-18 Merck Sharp & Dohme Corp. 3-aminosulfonyl substituted indole derivatives and methods of use thereof
US8367665B2 (en) 2008-04-16 2013-02-05 Karo Bio Ab Estrogen receptor ligands
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
PE20110368A1 (es) * 2008-08-18 2011-06-13 Univ Yale Moduladores de mif
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
EP2774927A1 (en) * 2008-12-03 2014-09-10 Presidio Pharmaceuticals, Inc. Inhibitors of HCV NS5A
TWI438200B (zh) * 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
NZ596144A (en) * 2009-04-06 2014-01-31 Ptc Therapeutics Inc Indole derivatives and methods for antiviral treatment
EP2416765B1 (en) 2009-04-06 2016-03-30 PTC Therapeutics, Inc. Hcv inhibitor and therapeutic agent combinations
US9198907B2 (en) 2009-04-06 2015-12-01 Ptc Therapeutics, Inc. Combinations of a HCV inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent
US8927576B2 (en) * 2009-04-06 2015-01-06 PTC Therpeutics, Inc. HCV inhibitor and therapeutic agent combinations
CA2763140A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
GB0917571D0 (en) 2009-10-07 2009-11-25 Karobio Ab Novel estrogen receptor ligands
AU2010324871A1 (en) 2009-11-25 2012-06-14 Merck Sharp & Dohme Corp. Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
JP2013512247A (ja) 2009-11-25 2013-04-11 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染症の治療または予防のための５−アルキニル−チオフェン−２−カルボン酸誘導体およびそれらの使用
CA2785488A1 (en) 2009-12-22 2011-07-21 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
US20130072523A1 (en) 2009-12-24 2013-03-21 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
EP2545060B1 (en) 2010-03-09 2015-11-25 Merck Sharp & Dohme Corp. Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
WO2011112191A1 (en) * 2010-03-11 2011-09-15 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
TW201141857A (en) 2010-03-24 2011-12-01 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
TW201139438A (en) 2010-03-24 2011-11-16 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
MX2012010918A (es) 2010-03-24 2013-01-18 Vertex Pharma Analogos para el tratamiento o prevencion de infecciones por flavivirus.
WO2011119870A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2011159826A2 (en) 2010-06-15 2011-12-22 Vertex Pharmaceuticals Incorporated Hcv ns5b protease mutants
EP2585447A2 (en) 2010-06-28 2013-05-01 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
WO2012006070A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
ES2626601T3 (es) 2010-06-28 2017-07-25 Bayer Intellectual Property Gmbh Compuestos heterocíclicos como pesticidas
WO2012018534A2 (en) 2010-07-26 2012-02-09 Schering Corporation Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
EP2621279B1 (en) 2010-09-29 2018-04-04 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
CN103269586B (zh) 2010-10-26 2015-07-15 普雷西迪奥制药公司 丙型肝炎病毒抑制剂
LT2658844T (lt) 2010-12-28 2017-02-10 Sanofi Nauji pirimidino dariniai, jų gamyba ir jų farmacinis panaudojimas kaip akt (pkb) fosforilinimo slopiklių
US9156872B2 (en) 2011-04-13 2015-10-13 Merck Sharp & Dohme Corp. 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP2696681B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
NO2686520T3 (no) 2011-06-06 2018-03-17
EP3251671A1 (en) 2011-06-06 2017-12-06 Akebia Therapeutics Inc. Compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
AU2012286853A1 (en) 2011-07-26 2013-05-02 Vertex Pharmaceuticals Incorporated Thiophene compounds
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
GB201113538D0 (en) 2011-08-04 2011-09-21 Karobio Ab Novel estrogen receptor ligands
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013039876A1 (en) 2011-09-14 2013-03-21 Merck Sharp & Dohme Corp. Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
EP2827876A4 (en) 2012-03-22 2015-10-28 Alios Biopharma Inc PHARMACEUTICAL COMBINATIONS WITH A THIONUCLEOTIDE ANALOG
DK3444238T3 (da) 2012-07-27 2022-01-03 Sato Pharma Fremgangsmåde til fremstilling af difluormethylenforbindelser
KR20150105302A (ko) 2012-11-05 2015-09-16 난트 홀딩스 아이피, 엘엘씨 헤지 호그 신호 경로의 억제제로서 환상 술폰아미드 함유 유도체
CA2815506C (en) 2012-12-12 2018-12-11 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
US9073946B2 (en) * 2013-01-15 2015-07-07 Kineta, Inc. Anti-viral compounds
EP2769723A1 (en) * 2013-02-22 2014-08-27 Ruprecht-Karls-Universität Heidelberg Compounds for use in inhibiting HIV capsid assembly
TW201526899A (zh) 2013-02-28 2015-07-16 Alios Biopharma Inc 醫藥組成物
SMT202400092T1 (it) 2013-06-13 2024-05-14 Akebia Therapeutics Inc Composizioni e metodi per il trattamento dell'anemia
JP6071825B2 (ja) * 2013-09-20 2017-02-01 株式会社東芝 不揮発性記憶装置
MX2016006325A (es) * 2013-11-15 2016-12-02 Wistar Inst Inhibidores del antígeno nuclear 1 de epstein-barr, y su método de uso.
EP3076964A1 (en) 2013-12-05 2016-10-12 Karo Pharma AB Estrogen receptor beta agonists for use in treating mesothelioma
CN106661009B (zh) * 2014-04-28 2019-11-26 江苏康缘药业股份有限公司 抗肠病毒71噻二唑烷衍生物
US10568876B2 (en) 2014-09-05 2020-02-25 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
US9828369B2 (en) 2014-09-05 2017-11-28 Merck Sharpe & Dohme Corp. Isoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
US9877957B2 (en) 2014-09-05 2018-01-30 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
HK1247201A1 (zh) 2015-01-23 2018-09-21 阿克比治疗有限公司 2-(5-(3-氟苯基)-3-羟基吡啶甲醯胺)乙酸的固体形式、其组合物及用途
PL3277270T3 (pl) 2015-04-01 2022-02-14 Akebia Therapeutics, Inc. Kompozycje i sposoby leczenia niedokrwistości
US10442788B2 (en) 2015-04-01 2019-10-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2016183266A1 (en) 2015-05-13 2016-11-17 Enanta Pharmaceuticals, Inc. Ehpatitis b antiviral agents
EP3294705B1 (en) 2015-05-14 2021-07-21 The Wistar Institute Of Anatomy And Biology Ebna1 inhibitors and methods using same
US10179131B2 (en) 2015-07-13 2019-01-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10301255B2 (en) 2015-07-22 2019-05-28 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10280175B2 (en) 2016-02-02 2019-05-07 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
KR102398439B1 (ko) 2016-03-07 2022-05-16 이난타 파마슈티칼스, 인코포레이티드 B형 간염 항바이러스제
EP3241830A1 (de) 2016-05-04 2017-11-08 Bayer CropScience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
SG11201810834WA (en) 2016-06-10 2018-12-28 Enanta Pharm Inc Hepatitis b antiviral agents
EP3497102B1 (de) 2016-08-15 2022-12-07 Bayer CropScience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
KR20190078646A (ko) 2016-11-18 2019-07-04 머크 샤프 앤드 돔 코포레이션 디아실글리세리드 o-아실트랜스퍼라제 2의 억제제로서 유용한 인다졸 유도체
CA3043206A1 (en) 2016-11-18 2018-05-24 Merck Sharp & Dohme Corp. Indole derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
EA202090514A1 (ru) 2017-08-28 2020-06-24 Энанта Фармасьютикалс, Инк. Противовирусное средство против гепатита в
US10723733B2 (en) 2017-12-06 2020-07-28 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
TW201927789A (zh) 2017-12-06 2019-07-16 美商因那塔製藥公司 B型肝炎抗病毒試劑
KR102730859B1 (ko) * 2017-12-20 2024-11-15 브리스톨-마이어스 스큅 컴퍼니 아릴 및 헤테로아릴 치환된 인돌 화합물
WO2019143902A2 (en) 2018-01-22 2019-07-25 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
CN111741958A (zh) 2018-02-21 2020-10-02 拜耳公司 作为害虫防治剂的稠合双环杂环衍生物
US10729688B2 (en) 2018-03-29 2020-08-04 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
CA3097219A1 (en) 2018-05-09 2019-11-14 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
WO2019222470A1 (en) 2018-05-17 2019-11-21 The Wistar Institute Ebna1 inhibitor crystalline forms, and methods of preparing and using same
CA3113235A1 (en) 2018-09-21 2020-03-26 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
PT3860998T (pt) 2018-10-05 2024-04-02 Annapurna Bio Inc Compostos e composições para o tratamento de condições associadas à atividade do recetor apj
IL283190B2 (en) 2018-11-21 2025-08-01 Enanta Pharm Inc Functionalized heterocycles as antiviral agents
UY38696A (es) 2019-05-14 2020-11-30 Vertex Pharma Moduladores de alfa-1 antitripsina
US11236111B2 (en) 2019-06-03 2022-02-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2020247575A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
WO2020247561A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
WO2021007488A1 (en) 2019-07-11 2021-01-14 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US11236108B2 (en) 2019-09-17 2022-02-01 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
US12612367B2 (en) 2019-12-10 2026-04-28 Akebia Therapeutics, Inc. Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
CA3177524A1 (en) * 2020-04-03 2021-10-07 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
EP4126863A1 (en) 2020-04-03 2023-02-08 Vertex Pharmaceuticals Incorporated 1 h-pyrazolo[4,3-g]isoquinoline and 1 h-pyrazolo[4,3-g]quinoline derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd)
WO2021203014A1 (en) 2020-04-03 2021-10-07 Vertex Pharmaceuticals Incorporated Pyrano[4,3-b]l ndole derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd)
CN116924959B (zh) * 2022-03-30 2025-08-19 山东大学 一种hdac11亚型选择性抑制剂及其制备方法和应用

Family Cites Families (233)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3530825A1 (de) * 1985-08-29 1987-03-05 Boehringer Mannheim Gmbh Neue benzodipyrrole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DD258016A1 (de) 1987-03-02 1988-07-06 Univ Leipzig Verfahren zur herstellung von 4-alkoxy-pyrido/3',2':4,5/thieno/3,2-d/pyrimidin-2-carbonsaeurealkylestern
DD258014A1 (de) 1987-03-02 1988-07-06 Univ Leipzig Verfahren zur herstellung von 4-oxo-3,4-dihydro-pyrido/3',2':4,5/-thieno/3,2-d/pyrimidin-2-carbonsaeurealkylestern
DD258015A1 (de) 1987-03-02 1988-07-06 Univ Leipzig Verfahren zur herstellung von gegebenfalls in 7,8- bzw. 8,9-stellung cycloaliphatisch verbrueckten 4-alkoxy-pyrido-/3',2':4,5/thieno/3,2-d/pyrimidin-2-carbonsaeuren
US4788206A (en) * 1987-07-10 1988-11-29 Hoffmann-La Roche Inc. Pentadieneamides
US5072003A (en) * 1989-04-24 1991-12-10 Amoco Corporation Acid anhydrides and dianhydrides of disubstituted maleic anhydrides
US5166170A (en) 1989-07-03 1992-11-24 Hoechst-Roussel Pharmaceuticals Incorporated 2-(aminoaryl) indoles and indolines as topical antiinflammatory agents for the treatment of skin disorders
US5034393A (en) 1989-07-27 1991-07-23 Dowelanco Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives
JPH03246540A (ja) 1989-11-07 1991-11-01 Fuji Photo Film Co Ltd 直接ポジカラー写真感光材料
JP2649980B2 (ja) 1989-11-27 1997-09-03 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
US5120752A (en) 1989-12-28 1992-06-09 Abbott Laboratories Cyclopropyl derivative lipoxygenase inhibitors
US5118695A (en) * 1990-08-06 1992-06-02 Eastman Kodak Company 1-hydroxyindole fungicides
IL99161A (en) 1990-08-17 1996-11-14 Takeda Chemical Industries Ltd History of guanidine A process for their preparation and preparations from pesticides that contain them
US5210092A (en) 1990-09-25 1993-05-11 Fujisawa Pharmaceutical Co., Ltd. Angiotensin ii antagonizing heterocyclic derivatives
PH31175A (en) 1990-10-31 1998-03-20 Squibb & Sons Inc Indole and benzimi-dazole-substituted imidazole and benzimidazole derivatives.
JP2651755B2 (ja) 1991-03-01 1997-09-10 富士写真フイルム株式会社 ハロゲン化銀カラー写真感光材料
US5190942A (en) * 1991-04-22 1993-03-02 E. R. Squibb & Sons, Inc. Benzoxazole and related heterocyclic substituted imidazole and benzimidazole derivatives
US5527819A (en) * 1991-09-06 1996-06-18 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
GB9201789D0 (en) 1992-01-28 1992-03-11 Fujisawa Pharmaceutical Co Heterocyclic derivatives
US5354759A (en) * 1991-09-12 1994-10-11 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic compounds
US5693643A (en) * 1991-09-16 1997-12-02 Merck & Co., Inc. Hydantoin and succinimide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
JPH05255089A (ja) 1991-12-18 1993-10-05 Sanwa Kagaku Kenkyusho Co Ltd 抗ウイルス剤
JP2963288B2 (ja) 1992-01-14 1999-10-18 株式会社海洋バイオテクノロジー研究所 水中有害付着生物防除剤
US5215980A (en) * 1992-01-17 1993-06-01 Merck & Co., Inc. 10-AZA-9-deoxo-11-deoxy-erythromycin A and derivatives thereof
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
SG65570A1 (en) 1992-02-25 1999-06-22 Recordati Chem Pharm Heterobicyclic compounds
US5605896A (en) * 1992-02-25 1997-02-25 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 adrenergic and 5HT1A activities
US5474994A (en) * 1992-05-26 1995-12-12 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 -adrenergic and 5HT1A
US5610054A (en) * 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
US5314898A (en) 1992-06-29 1994-05-24 Merck & Co., Inc. Aryl thiopyrano[4,3,2-cd]indoles as inhibitors of leukotriene biosynthesis
GB9218334D0 (en) * 1992-08-28 1992-10-14 Ici Plc Heterocyclic compounds
US5922857A (en) * 1992-09-28 1999-07-13 Chiron Corporation Methods and compositions for controlling translation of HCV proteins
WO1994008962A1 (en) * 1992-10-14 1994-04-28 Merck & Co., Inc. Fibrinogen receptor antagonists
GB9226537D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
RU2139052C1 (ru) 1993-03-31 1999-10-10 Мерк Энд Ко., Инк. Комбинация ингибитора вич-протеазы с другими антивирусными соединениями, фармацевтическая композиция на их основе и способ получения фармацевтической композиции
CA2121391A1 (en) 1993-04-28 1994-10-29 Atsuyuki Kojima Indoloylguanidine derivatives
US5681954A (en) * 1993-05-14 1997-10-28 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives
RU2124511C1 (ru) 1993-05-14 1999-01-10 Фармасьютикал Ко., Лтд Производные пиперазина
EP0628559B1 (en) 1993-06-10 2002-04-03 Beiersdorf-Lilly GmbH Pyrimidine compounds and their use as pharmaceuticals
DE4321030A1 (de) 1993-06-24 1995-01-05 Bayer Ag 4-bicyclisch substituierte Dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimittel
US5369120A (en) * 1993-07-28 1994-11-29 Warner-Lambert Company Pharmaceutical composition of 7-((substituted)amino-8-((substituted)carbonyl)-(methylamino)-1-oxasp iro(4,5)decanes and L-dopa
GB2282808A (en) 1993-10-14 1995-04-19 Merck & Co Inc 3-substituted heterocyclic indoles as inhibitors of HIV reverse transcriptase
GB2292149A (en) 1994-08-09 1996-02-14 Ferring Res Ltd Peptide inhibitors of pro-interleukin-1beta converting enzyme
US5502071A (en) 1994-08-19 1996-03-26 American Cyanamid Company Indoles as insecticides and acaricides
US5639906A (en) * 1994-10-11 1997-06-17 The United States Of America As Represented By The Department Of Health And Human Services Fluorescent and NMR sensitive pH indicators
IL115582A0 (en) * 1994-10-14 1996-01-19 Lilly Co Eli Methods for treating resistant tumors
CA2160600A1 (en) 1994-10-18 1996-04-19 Masahumi Kitano Indoloylguanidine derivatives
US5589482A (en) 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
KR100430059B1 (ko) * 1995-04-10 2004-09-24 후지사와 야꾸힝 고교 가부시키가이샤 cGMP-PDE억제제로서의인돌유도체
US6376529B1 (en) * 1995-06-07 2002-04-23 Peng Cho Tang Mono- and bis-indolylquinones and prophylactic and therapeutic uses thereof
JP2000503984A (ja) * 1996-01-22 2000-04-04 藤沢薬品工業株式会社 チアゾリルベンゾフラン誘導体およびその医薬組成物
US5633388A (en) * 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US5985910A (en) * 1996-04-19 1999-11-16 American Home Products Corporation 3- [4- (2- Phenyl-Indole-1-ylmethyl) Phenyl]- Acrylamides as estrogenic agents
ES2162198T3 (es) 1996-04-19 2001-12-16 American Home Prod Agentes estrogenos.
US5880137A (en) * 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US6384022B1 (en) * 1996-06-17 2002-05-07 Guilford Pharmaceuticals Inc. Prodrugs of NAALAdase inhibitors
US5977090A (en) * 1996-09-27 1999-11-02 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors
EP0927167A1 (en) * 1996-08-14 1999-07-07 Warner-Lambert Company 2-phenyl benzimidazole derivatives as mcp-1 antagonists
JP4056593B2 (ja) * 1996-08-26 2008-03-05 チバ スペシャルティ ケミカルズ ホールディング インコーポレーテッド 染料混合物、その製造方法及びその用途
AU726374B2 (en) * 1997-03-05 2000-11-02 University Of Washington Novel screening methods to identify agents that selectively inhibit hepatitis C virus replication
US6809088B2 (en) * 1997-03-24 2004-10-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them
US6335445B1 (en) * 1997-03-24 2002-01-01 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them
US6194599B1 (en) * 1997-04-08 2001-02-27 Catalytica, Inc. Process for preparing biaryl compounds
US5922898A (en) * 1997-04-08 1999-07-13 Catalytica Pharmaceuticals, Inc. Process for preparing biaryl compounds
US6326392B1 (en) * 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
AU2201699A (en) * 1997-12-19 1999-07-12 Eli Lilly And Company Hypoglycemic imidazoline compounds
US6506758B2 (en) * 1997-12-24 2003-01-14 Smithkline Beecham Laboratoires Pharmceutiques Indole derivatives useful A.O. for the treatment of osteoporosis
US6194419B1 (en) * 1997-12-26 2001-02-27 Takeda Chemical Industries, Ltd. Nitrogen-containing heterocyclic compounds, their production and use
US6410584B1 (en) * 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
WO1999051587A1 (en) * 1998-04-01 1999-10-14 Ono Pharmaceutical Co., Ltd. Fused thiophene derivatives and drugs containing the same as the active ingredient
US6221902B1 (en) * 1998-05-12 2001-04-24 American Home Products Corporation Biphenyl sulfonyl aryl carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
US6589954B1 (en) * 1998-05-22 2003-07-08 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
US6358992B1 (en) * 1998-11-25 2002-03-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with indole derivatives
US6685931B1 (en) * 1998-12-22 2004-02-03 Schering Corporation Treatment of hepatitis C virus infections with interleukin-10
US6265403B1 (en) * 1999-01-20 2001-07-24 Merck & Co., Inc. Angiogenesis inhibitors
AU5425400A (en) * 1999-04-12 2000-11-14 University Of Madras A pharmaceutical formulation useful for the treatment of hepatitis B, hepatitis C and other viral infections of the liver and a process for its preparation
US20020169101A1 (en) * 1999-05-10 2002-11-14 Gonzalez Maria Isabel Treatment of sexual dysfunction
WO2000073269A2 (en) 1999-06-02 2000-12-07 Regents Of The University Of Minnesota Nicotine receptor ligands
US6683115B2 (en) * 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
US20030176697A1 (en) * 1999-06-30 2003-09-18 The Regents Of The University Of California Method for preparing crambescidin core acid intermediates and their use for preparing crambescidin alkaloid analogs as therapeutic agents
US6380166B1 (en) * 1999-09-13 2002-04-30 American Home Products Corporation Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
JP2003509412A (ja) 1999-09-17 2003-03-11 シーオーアール セラピューティクス インコーポレイテッド Ｘａ因子阻害剤
BR0007174A (pt) 1999-09-28 2001-09-04 Basf Ag Composto, preparação farmacêutica e uso de compostos
US6770666B2 (en) * 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
EP1162196A4 (en) * 1999-12-27 2003-04-16 Japan Tobacco Inc COMPOUNDS WITH JOINED CYCLES AND THEIR USE AS MEDICAMENTS
CO5271696A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Procedimiento para reducir la morbilidad y el riesgo de mortalidad
CO5271697A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
CO5271709A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
US20020169107A1 (en) * 2001-01-19 2002-11-14 Mallinckrodt Inc. Novel aromatic azides for type I phototherapy
AU2868601A (en) 2000-01-27 2001-08-07 Ribotargets Ltd Biaryl compounds, their preparation and their use in therapy
DE10005631A1 (de) 2000-02-09 2001-08-23 Max Planck Gesellschaft Arginin-Mimetika als Faktor X¶a¶-Inhibitoren
WO2001064678A2 (en) 2000-02-29 2001-09-07 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
US7566765B2 (en) * 2000-03-06 2009-07-28 Rigel Pharmaceuticals, Inc. Heterocyclic compounds containing a nine-membered carbon-nitrogen ring
US7091240B2 (en) * 2000-03-10 2006-08-15 Oxigene, Inc. Tubulin binding ligands and corresponding prodrug constructs
AU2001241128A1 (en) 2000-03-14 2001-09-24 Fujisawa Pharmaceutical Co. Ltd. Novel amide compounds
WO2001074773A2 (en) 2000-03-31 2001-10-11 Ortho Mcneil Pharmaceutical, Inc. Phenyl-substituted indoles as histamine h3-receptor antagonists
US20020013327A1 (en) 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
PT1277736E (pt) 2000-04-28 2007-10-12 Asahi Kasei Pharma Corp Novos compostos bicíclicos
DE10022925A1 (de) 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
JP2002030069A (ja) 2000-07-17 2002-01-29 Japan Science & Technology Corp 縮合ピロール類の製造法
EP1177787A3 (en) 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts
JP2002105081A (ja) 2000-07-28 2002-04-10 Nikken Chem Co Ltd 新規チオフェンニ環化合物
US7270800B2 (en) * 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
DK1334091T3 (da) 2000-08-24 2012-10-15 Univ Pittsburgh Thioflavinderivater og deres anvendelse til diagnose og terapi af Alzheimer's sygdom
EP1192945A3 (en) 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
WO2002026696A1 (en) 2000-09-29 2002-04-04 Prolifix Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
JP4975941B2 (ja) 2000-09-29 2012-07-11 トポターゲット ユーケー リミテッド （ｅ）−ｎ−ヒドロキシ−３−（３−スルファモイル−フェニル）アクリルアミド化合物及びその治療用途
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
IL145838A (en) 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis
AU2002216649A1 (en) 2000-10-31 2002-05-15 Lynn Bonham Benzoxazole lpaat- beta inhibitors and uses thereof
AU2002220244A1 (en) 2000-11-02 2002-05-15 Influx, Inc. Azole containing compositions with enhanced antifungal activity
DE10063008A1 (de) 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
CA2433100A1 (en) 2000-12-27 2002-07-04 Helmut Haning Indole derivatives as ligands of thyroid receptors
ATE524441T1 (de) 2000-12-28 2011-09-15 Daiichi Seiyaku Co Vla-4-inhibitoren
ES2294047T3 (es) 2000-12-28 2008-04-01 Ono Pharmaceutical Co., Ltd. Un compuesto de ciclopenta (d) pirazolo(1,5-a) pirimidina como antagonista del receptor de crf.
JP2004520347A (ja) 2001-01-15 2004-07-08 グラクソ　グループ　リミテッド Ｌｄｌ−受容体発現のインデューサーとしてのアリールピペリジンおよびピペラジン誘導体
AU781168B2 (en) 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
WO2002060374A2 (en) 2001-01-29 2002-08-08 Insight Strategy And Marketing Ltd Benz-1,3-azole derivatives and their uses as heparanase inhibitors
CA2436133A1 (en) 2001-01-29 2002-08-08 University Of Connecticut Receptor selective cannabimimetic aminoalkylindoles
SE0100567D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
AU2002247208A1 (en) 2001-03-05 2002-09-19 Icos Corporation Selective pde3b inhibitors and use of the same in therapy
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
ATE460163T1 (de) 2001-04-12 2010-03-15 Pharmacopeia Llc Arly und diaryl piperidinderivate verwendbar als mch-hemmer
US6673775B2 (en) * 2001-04-18 2004-01-06 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US6825201B2 (en) * 2001-04-25 2004-11-30 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic amidopiperazine derivatives
JP2004535411A (ja) 2001-05-25 2004-11-25 ブリストルーマイヤーズ スクイブ カンパニー マトリックスメタロプロテナーゼ及び／またはＴＮＦ−α転換酵素（ＴＡＣＥ）の阻害剤としてのヒダントイン及び関連複素環化合物
WO2003000690A1 (en) 2001-06-25 2003-01-03 Aventis Pharmaceuticals Inc. Synthesis of heterocyclic compounds employing microwave technology
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
WO2003004458A1 (en) 2001-07-03 2003-01-16 Biovitrum Ab New compounds
EP1406889A2 (en) 2001-07-09 2004-04-14 Pharmacia Italia S.p.A. Interaction inhibitors of tcf-4 with beta-catenin
EP2335700A1 (en) * 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US7294457B2 (en) * 2001-08-07 2007-11-13 Boehringer Ingelheim (Canada) Ltd. Direct binding assay for identifying inhibitors of HCV polymerase
US7115741B2 (en) 2001-09-06 2006-10-03 Levy Daniel E 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
CN100348569C (zh) 2001-11-30 2007-11-14 伯哈姆学院 癌细胞中编程性细胞死亡的诱导
IL162533A0 (en) 2001-12-19 2005-11-20 Atherogenics Inc Chalcone derivatives and their use to treat diseases
WO2003053359A2 (en) 2001-12-19 2003-07-03 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
AU2002347022A1 (en) 2001-12-20 2003-07-09 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
WO2003053941A2 (en) 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases
TW200301698A (en) 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
JP2005519915A (ja) 2002-01-18 2005-07-07 セレテック・リミテッド・ライアビリティ・カンパニー Ｅｄｇ受容体に関連する症状の処置方法
US6930070B2 (en) * 2002-01-28 2005-08-16 Univation Technologies, Llc Heterocyclic nitrogen-containing activators and catalyst systems for olefin polymerization
WO2003064539A1 (en) 2002-01-28 2003-08-07 Ciba Specialty Chemicals Holding Inc. Aqueous dye solutions
RU2004126671A (ru) 2002-02-06 2005-04-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Гетероарилсоединения, полезные в качестве ингибиторов gsk-3
DE10209520A1 (de) 2002-03-04 2003-09-25 4Sc Ag Neue Modulatoren von Kaliumkanälen
US20030220377A1 (en) * 2002-05-08 2003-11-27 Richard Chesworth Indole compounds and their use as estrogen agonists/antagonists
AU2003273179A1 (en) 2002-05-10 2003-12-12 Bristol-Myers Squibb Company 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors
US6690975B2 (en) * 2002-05-17 2004-02-10 Bistner Co., Ltd. Methods for treating hepatitis C
AU2003239508A1 (en) * 2002-05-21 2003-12-12 Bristol-Myers Squibb Company Indole compounds useful as impdh inhibitors
TW200400004A (en) 2002-05-22 2004-01-01 Novartis Ag Organic compounds
US6974870B2 (en) * 2002-06-06 2005-12-13 Boehringer Ingelheim Phamaceuticals, Inc. Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
AU2003249852A1 (en) 2002-07-01 2004-01-19 Merck Patent Gmbh Polymerizable, luminescent compounds and mixtures, luminescent polymer materials and their use
EP1532118A2 (en) * 2002-07-05 2005-05-25 Axxima Pharmaceuticals Aktiengesellschaft Imidazole compounds for the treatment of hepatitis c virus infections
US6972336B2 (en) * 2002-07-18 2005-12-06 Novartis Ag N-alkylation of indole derivatives
AU2003258022A1 (en) 2002-08-02 2004-02-23 Genesoft Pharmaceuticals, Inc. Biaryl compounds having anti-infective activity
JP2006500355A (ja) * 2002-08-07 2006-01-05 イデニクス（ケイマン）リミテツド Ｈｉｖ治療用の置換フェニルインドール類
WO2004014912A1 (en) 2002-08-08 2004-02-19 Ribapharm Inc. Improved synthesis for hydroxyalkylated heterocyclic bases
DE10237723A1 (de) 2002-08-17 2004-07-08 Aventis Pharma Deutschland Gmbh Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
US20050260126A1 (en) 2002-08-30 2005-11-24 Yukitsuka Kudo Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein
SE0202692D0 (sv) 2002-09-11 2002-09-11 Astrazeneca Ab Compounds
WO2004024655A2 (en) 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
AU2003282920A1 (en) * 2002-10-04 2004-05-04 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
JP2006505571A (ja) * 2002-10-15 2006-02-16 リゲル ファーマシューテイカルズ、インコーポレイテッド 置換されたインドール及びｈｃｖ阻害剤としてのその使用
EP1551795A1 (en) 2002-10-17 2005-07-13 Methylgene, Inc. Inhibitors of histone deacetylase
DE60309498T2 (de) 2002-10-18 2007-08-30 F. Hoffmann-La Roche Ag 4-piperazinylbenzolsulfonyl-indole mit 5-ht6 rezeptor-affinität
EP1556355A1 (en) 2002-10-21 2005-07-27 Chiron Corporation Inhibitors of glycogen synthase kinase 3
GB0224557D0 (en) 2002-10-22 2002-11-27 Glaxo Group Ltd Novel compounds
WO2004041781A1 (en) 2002-11-07 2004-05-21 Suven Life Sciences Limited Preparation of 3-aminoalkyl-substituted indole derivatives from phenylhydrazines and aminoketones
ATE468114T1 (de) 2002-11-08 2010-06-15 High Point Pharmaceuticals Llc Sichere chemische entkuppler zur behandlung von fettsucht
WO2004050035A2 (en) 2002-12-03 2004-06-17 Isis Pharmaceuticals, Inc. Benzimidazoles and analogs thereof as antivirals
US7223785B2 (en) * 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7098231B2 (en) * 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
CA2438032C (en) 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
EP1457485A1 (en) 2003-03-14 2004-09-15 Dompé S.P.A. Sulfonic acids, their derivatives and pharmaceutical compositions containing them
KR20050122210A (ko) 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
GB0307891D0 (en) * 2003-04-04 2003-05-14 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
WO2004093912A1 (ja) 2003-04-23 2004-11-04 Kyowa Hakko Kogyo Co. Ltd. 好中球性炎症疾患の予防および／または治療剤
BRPI0409916A (pt) 2003-04-30 2006-04-25 Inst For Pharm Discovery Inc ácidos carboxìlicos substituìdos com fenila
WO2004099168A2 (en) 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Substituted carboxylic acids
JP2006525366A (ja) 2003-04-30 2006-11-09 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー 複素環式カルボン酸置換基
US7358248B2 (en) 2003-04-30 2008-04-15 The Institute For Pharmaceutical Discovery Llc Substituted amino carboxylic acids
DE10320781A1 (de) 2003-05-09 2004-11-25 Bayer Healthcare Ag Acylierte Nonadepsipeptide
GB0313762D0 (en) 2003-06-13 2003-07-23 Biofocus Plc Compound libraries
NZ572901A (en) 2003-06-27 2010-06-25 Janssen Pharmaceutica Nv Tricyclic delta opioid modulators
DE10329860A1 (de) 2003-07-02 2005-01-20 Atto-Tec Gmbh Sulfonamidderivate polycyclischer Farbstoffe für analytische Anwendungen
AU2004259012C1 (en) 2003-07-23 2012-08-02 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
ES2228268B1 (es) 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
ES2222832B1 (es) 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
ES2228267B1 (es) 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
ES2222827B1 (es) 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
DE602004030017D1 (de) * 2003-08-01 2010-12-23 Chugai Pharmaceutical Co Ltd Heterocyclische verbindungen als nützliche malonyl-coa decarboxylase-hemmer
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
AU2004263190A1 (en) 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
KR20060079190A (ko) 2003-08-14 2006-07-05 아사히 가세이 파마 가부시키가이샤 치환 아릴알칸산 유도체 및 그의 용도
US7378409B2 (en) 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
EP1663972A1 (en) 2003-09-03 2006-06-07 Galapagos N.V. The claimed invention relates to novel 4-piperidinecarboxamide and the use thereof for the preparation of medicaments against 5-ht2a receptor-related disorders
US20050249697A1 (en) 2003-09-24 2005-11-10 Uhrich Kathryn E Compositions and methods for the inhibition of bone growth and resorption
US7211671B2 (en) * 2003-10-01 2007-05-01 Bristol Myers Squibb Company Substituted 1,3-dihydro-imidazol-2-one and 1,3-dihydro-imidazol-2-thione derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
US7223787B2 (en) * 2003-10-21 2007-05-29 Board Of Regents, The University Of Texas System Prenylation inhibitors reduce host cell permissiveness to viral replication
US20050119318A1 (en) * 2003-10-31 2005-06-02 Hudyma Thomas W. Inhibitors of HCV replication
EP1532980A1 (en) 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
PE20050897A1 (es) 2003-12-03 2005-11-06 Glaxo Group Ltd Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
US20050123560A1 (en) * 2003-12-04 2005-06-09 Sinnott Robert A. High purity and water dispersible extract and formulations of larrea tridentata leaf resin, and methods of making and using the same
WO2005058315A1 (en) 2003-12-12 2005-06-30 Ribapharm, Inc. Novel heterocyclic compounds as ikk2 inhibitors with anti-hbv activity
WO2005061519A1 (en) 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
WO2005062676A1 (ja) 2003-12-24 2005-07-07 Konica Minolta Holdings, Inc. 有機エレクトロルミネッセンス素子用材料、有機エレクトロルミネッセンス素子、照明装置および表示装置
JP2005194198A (ja) 2003-12-26 2005-07-21 Takeda Chem Ind Ltd チエノピリジン化合物
BRPI0506719A (pt) 2004-01-08 2007-05-02 Medivir Ab composto, composição farmacêutica, e, uso de um composto
US7253283B2 (en) 2004-01-16 2007-08-07 Bristol-Myers Squibb Company Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7875604B2 (en) 2004-02-04 2011-01-25 University Of Virginia Patent Foundation Compounds that inhibit HIV particle formation
BRPI0507626A (pt) 2004-02-11 2007-07-03 Irm Llc compostos e composiçoes como moduladores de lxr
UY28758A1 (es) 2004-02-20 2005-09-30 Boehringer Ingelheim Int Inhibidores de polimerasa viral
WO2005082905A1 (ja) 2004-02-26 2005-09-09 Kyowa Hakko Kogyo Co., Ltd. 二環性複素環化合物
US7371743B2 (en) 2004-02-28 2008-05-13 Boehringer Ingelheim International Gmbh Carboxylic acid amides, the preparation thereof and their use as medicaments
EP1574502A1 (en) 2004-03-08 2005-09-14 Novartis AG Use of pyrimidine compounds in the preparation of parasiticides
US20070276020A1 (en) 2004-03-08 2007-11-29 Boykin David W Dicationic Compounds For Activity Against Trichomonas Vaginalis
US8519158B2 (en) 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
BRPI0510717B8 (pt) 2004-05-06 2021-05-25 Bioresponse Llc uso de 3,3' diindolilmetano (dim) ou 2-(indol-3-ilmetil)-3,3´-diindolilmetano (ltr)
US9523031B2 (en) 2004-05-14 2016-12-20 Idemitsu Kosan Co., Ltd. Organic electroluminescent device
DE102004024504A1 (de) 2004-05-18 2006-02-16 Bayer Healthcare Ag Neue Cylopenta[b]benzofuran-Derivate und ihre Verwendung
EP1771169A1 (en) 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Methods for treating hepatitis c
FI20041129A0 (fi) 2004-08-30 2004-08-30 Ctt Cancer Targeting Tech Oy Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi
KR20070060156A (ko) 2004-10-04 2007-06-12 미리어드 제네틱스, 인크. 알츠하이머병 치료용 화합물
US20080319044A1 (en) 2004-11-01 2008-12-25 Nuada, Llc Compounds and Methods of Use Thereof
JP2006131519A (ja) 2004-11-04 2006-05-25 Idemitsu Kosan Co Ltd 縮合環含有化合物及びそれを用いた有機エレクトロルミネッセンス素子
KR20070086155A (ko) 2004-11-25 2007-08-27 닛산 가가쿠 고교 가부시키 가이샤 인돌 화합물의 제조방법
WO2006083458A2 (en) 2004-12-30 2006-08-10 Bioresponse Llc Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associates conditions

Also Published As

Publication number Publication date
MX2007000481A (es) 2007-03-29
US8013006B2 (en) 2011-09-06
KR20070083484A (ko) 2007-08-24
US20080096928A9 (en) 2008-04-24
AU2005275181A1 (en) 2006-02-23
ECSP077252A (es) 2007-05-30
US20120009142A1 (en) 2012-01-12
US20060223863A1 (en) 2006-10-05
EA200700243A1 (ru) 2007-08-31
IL180645A0 (en) 2008-04-13
CA2573185A1 (en) 2006-02-23
EP1771169A1 (en) 2007-04-11
BRPI0511834A (pt) 2008-01-08
JP2008506702A (ja) 2008-03-06
WO2006019831A1 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
EA200700243A1 (ru) Способы лечения гепатита с
JO2318B1 (en) Nucleoside derivatives used as DNA-based viral RNA inhibitors
WO2004007512A3 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2004000858A3 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
TW200733953A (en) Materials and methods for treating viral infections
NO20051969L (no) Nukleosidderivater for behandling av hepatitt C virusinfeksjon.
BRPI0415883A (pt) compostos e composições de nucleosìdeo para o tratamento de infecções virais
EA200900298A1 (ru) Ингибиторы вируса гепатита с
ATE522528T1 (de) Virale inhibitoren
ZA200805304B (en) Anti-viral compounds
WO2006012078A3 (en) Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
DE60319820D1 (de) Pyrazoloä1,5-aüpyrimidin-verbindungen als antivirale agentien
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
ATE505475T1 (de) Nukleosidderivate als inhibitoren viraler polymerasen
DE60143672D1 (de) Modifizierte nukleoside zur behandlung von virusinfektionen und abnormaler zellulärer proliferation
DK1569929T3 (da) Forbindelser og fremgangsmåder til behandling eller forebyggelse af flavi-virusinfektioner
ATE475660T1 (de) Antivirale verbindungen
DK1644363T3 (da) Triheterocykliske forbindelser, sammensætninger og fremgangsmåder til behandling af cancer eller virussygdomme
WO2010055164A3 (en) Isoquinolone derivatives as inhibitors of plavivirus replication
EA201000201A1 (ru) Азотсодержащие бициклические химические вещества для лечения вирусных инфекций
UY27798A1 (es) Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatits c y composiciones y tratamientos que los usan.
ATE505473T1 (de) Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c
WO2007025043A3 (en) Seven-membered ring nucleosides
ATE498398T1 (de) Cycloalkyl-heterozyklen zur behandlung des hepatitis-c-virus
ATE337309T1 (de) Pyranon- und pyrandioninhibitoren der rna- abhängigen rna-polymerase des hepatitis-c-virus

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application